Evaluation of effects of chitosan in preventing hemorrhagic cystitis in rats induced by cyclophosphamide.
Hemorrhagic cystitis is a common problem following cyclophosphamide or radiation therapy. Chitosan has been shown to be an effective hemostatic agent and promoter of wound healing in animal experiments. We evaluated the safety and efficacy of intravesical chitosan in an animal model of cyclophosphamide cystitis. Hemorrhagic cystitis was induced in female F344 rats by intraperitoneal cyclophosphamide, 100 mg/kg. Chitosan solution (0.3 ml) was instilled intravesically on day 1 (Group 1), on days 1, 3, and 5 (Group 2), or 1 hour after the administration of cyclophosphamide (Group 3). The rats in group 4 were treated with chitosan diluent on day 1 after cyclophosphamide, and the rats in group 5 received intravesical chitosan without cyclophosphamide. Sequential examination revealed decreased mortality and lower incidences of severe bladder bleeding, necrosis and inflammation in Group 3. Treatment delayed until after the appearance of the cystitis, especially repeated treatments, appeared to make the cyclophosphamide-induced changes worse. Used within 1 hour of cyclophosphamide administration, before the cystitis develops, chitosan seemed to have the possibility to inhibit the appearance of hemorrhagic cystitis. In addition to the changes in the bladder, severe changes occurred in the kidneys secondary to cyclophosphamide.
Okamura
T
T
Department of Urology, Nagoya City University Medical School.
Masui
T
T
St John
M K
MK
Cohen
S M
SM
Taylor
R J
RJ
D000283:Administration, Intravesical; D000818:Animals; D002686:Chitin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D048271:Chitosan; D003520:Cyclophosphamide / Q000633:toxicity*; D003556:Cystitis / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D006490:Hemostatics / Q000008:administration & dosage / Q000627:therapeutic use*; D007668:Kidney / Q000473:pathology; D008297:Male; D051381:Rats; D011916:Rats, Inbred F344; D001745:Urinary Bladder Diseases / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*
D006490:Hemostatics; D002686:Chitin; D003520:Cyclophosphamide; D048271:Chitosan